Multicenter Population Pharmacokinetics and Exposure–Efficacy Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Tóm tắt
Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). This study aimed to characterize the population pharmacokinetics (PK) and exposure–efficacy analysis of pirfenidone in patients with IPF. Data from 10 hospitals with 106 patients were used to develop a population PK model. The annual decline in forced vital capacity (FVC) over 52 weeks was integrated with pirfenidone plasma concentration to characterize the exposure–efficacy relationship. A linear one-compartment model with first-order absorption and elimination processes and lag time best described the pirfenidone PK. The population estimates of clearance and central volume of distribution at steady-state were 13.37 L/h and 53.62 L, respectively. Bodyweight and food were statistically correlated with PK variability but had no significant influence on pirfenidone exposure. Annual decline in FVC with pirfenidone plasma concentration was described by a maximum drug effect (Emax) model. The typical EC50 was 1.73 mg/L (1.18–2.31 mg/L) and the corresponding EC80 was 2.18 mg/L (1.49–2.87 mg/L). Simulations showed that two dosing regimens of 500 and 600 mg three times daily were predicted to generate 80% of the Emax. In patients with IPF, covariates such as bodyweight and food might not be sufficient for dose adjustment, and a low dose of 1500 mg/day could also provide 80% of the Emax, as the standard dose (1800 mg/day).
Tài liệu tham khảo
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Resp Crit Care Med. 2022;205(9):e18–47.
Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev. 2019;28(153): 190021.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.
Aimo A, Cerbai E, Bartolucci G, Adamo L, Barison A, Lo Surdo G, Biagini S, Passino C, Emdin M. Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res. 2020;155: 104694.
Rubino C, Bhavnani S, Ambrose P, Forrest A, Loutit J. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–85.
Shi SJ, Wu JH, Chen HT, Chen H, Wu J, Zeng FD. Single-and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007;47(10):1268–76.
Salvatore SOTGIA, Alessandro GFRC, Elisabetta SFDC, Angelo ZCF, Panagiotis PDC, Arduino AM, et al. Micellar electrokinetic capillary chromatographic determination of pirfenidone and 5-carboxy-pirfenidone by direct injection of plasma from patients receiving treatment for idiopathic pulmonary fibrosis (IPF). Microchem J. 2020;154:104536.
Barranco-Garduño LM, Buendía-Roldan I, Rodriguez JJ, González-Ramírez R, Cervantes-Nevárez AN, Neri-Salvador JC, et al. Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Heliyon. 2020;6(10): e05279.
Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al. Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Cells. 2022;11(1):143.
Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015;53(5):232–41.
Song MJ, Moon SW, Choi JS, Lee SH, Lee SH, Chung KS, et al. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Sci Rep. 2020;10(1):1–8.
Lee EG, Lee T-H, Hong Y, Ryoo J, Heo JW, Gil BM, et al. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real-world study. PLoS ONE. 2021;16(12): e0261684.
Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, et al. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respir Res. 2018;5(1): e000323.
Song MJ, Lee SH, Jung JY, Kang YA, Park MS, Kim YS, et al. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study. BMC Pulm Med. 2021;21(1):145.
Wang PL, Sun HT, Gao MM, Zhang GJ, Zhang XJ, Yang J. UPLC-MS/MS method for determination of pirfenidone and its metabolite in plasma and its application for pharmacokinetics research in patients with idiopathic pulmonary fiber. Chin Pharm J. 2021;56(8):675–81.
Kidney FN. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. New Engl J Med. 2014;370(22):2083–92.
Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Phar. 2001;28(5):481–504.
Morrey JD, Korba BE, Beadle JR, Wyles DL, Hostetler KY. Alkoxyalkyl esters of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. Antimicrob Agents Chemother. 2009;53(7):2865–70.
Huang NY, Ding L, Wang J, Zhang QY, Liu X, Lin HD, et al. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions. Drug Res. 2013;63(08):388–95.
Hu J, Shang D, Xu X, He X, Ni X, Zhang M, et al. Effect of grapefruit juice and food on the pharmacokinetics of pirfenidone in healthy Chinese volunteers: a diet-drug interaction study. Xenobiotica. 2016;46(6):516–21.
Schrag M, Regal K. Pharmacokinetics and toxicokinetics. In: Faqi AS, editor. A comprehensive guide to toxicology in preclinical drug development. New York: Academic Press; 2013. p. 31–68.
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.
Kumari N, Bhattacharya B, Roy P, Michalchuk AAL, Emmerling F, Ghosh A. Enhancing the pharmaceutical properties of pirfenidone by mechanochemical cocrystallization. Cryst Growth Des. 2019;19(11):6482–92.
Kim ES, Keating GM. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs. 2015;75(2):219–30.
US FDA. Esbriet (pirfenidone) capsules: US prescribing information. US FDA; 2014. Available at: http://www.accessdata.fda.gov.
Koonrungsesomboon N, Khatsri R, Wongchompoo P, Teekachunhatean S. The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. Pharmacogenomics J. 2018;18(6):760–8.
Amundson WH, Lee A, Bishop JR, Kim HJ. Frequency of single nucleotide polymorphisms of five genes in idiopathic pulmonary fibrosis patients treated with pirfenidone. In: American Thoracic Society 2019 International Conference; 2019, vol. 199, p. A5260.
European Medicines Agency. Esbriet (pirfenidone) hard capsules: EU summary of product characteristics. European Medicines Agency; 2014. Available at: http://www.ema.europa.eu.
Kale V, Manoi T, Porter C, Atkinson S. Drug interaction of pirfenidone with commonly prescribed pharmaceutical drugs. FASEB J. 2016;30(Suppl 1):lb545.
Aimo A, Cerbai E, Bartolucci G, Adamo L, Emdin M. Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res. 2020;155: 104694.
Schmid U, Weber B, Magnusson MO, Freiwald M. Exposure–efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Resp Med. 2021;180(12): 106369.